Clinical Trials
6 trialsNCT03219268 2023-12-21
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
MacroGenics
Phase 1 Completed
NCT01792882 2023-02-28
GBCPRT0008
Global BioClinical
Withdrawn
NCT03082209 2022-12-09
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
AbbVie
Phase 1 Completed
NCT02431260 2019-06-14
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT01831726 2017-03-20
SIGNATURE
Novartis
Phase 2 Completed
NCT02002689 2016-05-02
SIGNATURE
Novartis
Phase 2 Terminated